Michael G Hanna Selected Research

Myokymia

4/2014	Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.
6/2012	Paroxysmal neuromyotonia: a new sporadic channelopathy.
11/2009	Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter release.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael G Hanna Research Topics

Disease

20	Channelopathies 06/2022 - 07/2002
19	Paralysis (Palsy) 07/2021 - 08/2002
18	Myotonia 10/2021 - 10/2010
18	Mitochondrial Diseases (Mitochondrial Disease) 12/2020 - 03/2004
11	Muscular Diseases (Myopathy) 01/2022 - 03/2005
11	Epilepsy (Aura) 01/2020 - 07/2002
10	Inclusion Body Myositis 02/2022 - 11/2004
8	Ataxia (Dyssynergia) 06/2022 - 12/2004
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 03/2004
7	Type 1 Episodic Ataxia 06/2022 - 04/2007
7	Myotonia Congenita (Thomsen Disease) 01/2022 - 11/2008
6	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2021 - 03/2013
6	Neoplasms (Cancer) 04/2017 - 07/2006
5	Myositis (Idiopathic Inflammatory Myopathies) 02/2022 - 11/2004
5	Hyperkalemic Periodic Paralysis 07/2021 - 08/2002
5	Hypokalemic Periodic Paralysis (Periodic Paralysis, Hypokalemic) 11/2019 - 10/2010
5	Disease Progression 01/2019 - 05/2011
5	Neuromuscular Diseases (Neuromuscular Disease) 12/2018 - 01/2015
4	Nervous System Diseases (Neurological Disorders) 01/2020 - 07/2002
4	Muscular Atrophy (Muscle Atrophy) 01/2019 - 05/2013
4	X-Linked Bulbo-Spinal Atrophy 01/2019 - 05/2011
4	Chronic Progressive External Ophthalmoplegia (Progressive External Ophthalmoplegia) 06/2017 - 10/2003
4	Motor Neuron Disease (Primary Lateral Sclerosis) 07/2014 - 05/2011
4	Cerebellar Ataxia (Dysmetria) 01/2012 - 11/2009
4	Episodic Ataxia 06/2010 - 12/2004
4	Migraine Disorders (Migraine) 04/2007 - 07/2002
3	Andersen Syndrome 01/2022 - 04/2013
3	Myotonic Dystrophy (Dystrophia Myotonica) 10/2021 - 07/2013
3	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 03/2021 - 03/2005
3	Brain Diseases (Brain Disorder) 01/2020 - 03/2006
3	Type 2 Episodic Ataxia 02/2016 - 10/2008
3	Seizures (Absence Seizure) 01/2016 - 01/2002
3	Myotonic Disorders (Paramyotonia Congenita) 11/2014 - 01/2011
3	Myokymia 04/2014 - 11/2009
3	MELAS Syndrome (Syndrome, MELAS) 02/2010 - 01/2003
2	Stroke (Strokes) 01/2022 - 01/2003
2	Atrophy 01/2022 - 01/2020
2	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2021
2	Muscle Weakness 07/2021 - 06/2017
2	Contracture 07/2021 - 11/2009
2	Inborn Genetic Diseases (Disease, Hereditary) 07/2021 - 01/2019
2	Malignant Hyperthermia 01/2020 - 10/2016
2	Sudden Infant Death (SID) 01/2020 - 01/2018
2	Leigh Disease (Leigh's Disease) 01/2019 - 01/2019
2	Myalgia 01/2018 - 08/2011
2	Dermatomyositis (Dermatopolymyositis) 01/2017 - 04/2016
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2016 - 04/2010
2	Cytochrome-c Oxidase Deficiency 12/2013 - 06/2013
2	Isaacs Syndrome (Neuromyotonia) 10/2013 - 01/2002
2	Rare Diseases (Rare Disease) 07/2013 - 10/2012
2	Colonic Neoplasms (Colon Cancer) 08/2012 - 07/2006
2	Lactic Acidosis 06/2003 - 01/2003
1	Sensorineural Hearing Loss 01/2022

Drug/Important Bio-Agent (IBA)

18	Mitochondrial DNA (mtDNA)IBA 01/2022 - 01/2003
15	Ion Channels (Ion Channel)IBA 07/2021 - 07/2002
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
10	SodiumIBA 11/2020 - 10/2007
10	Sodium Channels (Sodium Channel)IBA 01/2020 - 08/2002
9	Chloride Channels (Chloride Channel)IBA 01/2022 - 11/2008
7	Androgen Receptors (Androgen Receptor)IBA 01/2019 - 05/2011
7	Calcium Channels (Calcium Channel)IBA 02/2016 - 12/2004
6	Voltage-Gated Sodium ChannelsIBA 10/2021 - 11/2014
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2013
6	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 02/2011
5	PotassiumIBA 06/2022 - 04/2007
5	Mexiletine (Mexitil)FDA LinkGeneric 10/2021 - 01/2011
5	CalciumIBA 01/2020 - 07/2014
4	Potassium Channels (Potassium Channel)IBA 01/2022 - 12/2010
4	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020 - 11/2004
4	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 01/2020 - 10/2010
4	voltage-dependent calcium channel (P-Q type)IBA 02/2016 - 12/2004
4	polyglutamineIBA 07/2014 - 05/2011
3	Lactic Acid (Lactate)FDA LinkGeneric 01/2022 - 01/2019
3	ADP-ribosylarginine hydrolaseIBA 12/2021 - 01/2018
3	Amino Acids FDA Link 12/2020 - 01/2017
3	Arginine (L-Arginine)FDA Link 11/2019 - 10/2010
3	Peptides (Polypeptides)IBA 01/2018 - 04/2016
3	AntigensIBA 08/2012 - 07/2006
2	Biological ProductsIBA 03/2021 - 11/2015
2	Acetazolamide (Diamox)FDA LinkGeneric 02/2021 - 01/2019
2	Dichlorphenamide (Daranide)FDA Link 01/2021 - 04/2016
2	bimagrumabIBA 01/2021 - 01/2019
2	Pharmaceutical PreparationsIBA 11/2019 - 01/2002
2	AutoantibodiesIBA 01/2019 - 04/2016
2	Spider Venoms (Venom, Spider)IBA 01/2019 - 01/2018
2	ribonuclease HIIBA 06/2017 - 01/2016
2	Valosin Containing ProteinIBA 11/2016 - 03/2016
2	arimoclomolIBA 03/2016 - 03/2013
2	Neurotransmitter Agents (Neurotransmitter)IBA 02/2016 - 11/2009
2	Q-Type Calcium Channels (Q-Type Calcium Channel)IBA 01/2016 - 01/2012
2	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 12/2013 - 06/2013
2	ChloridesIBA 07/2013 - 08/2011
2	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2013 - 11/2012
2	N-desmethylstobadineIBA 10/2012 - 10/2010
2	VaccinesIBA 08/2012 - 07/2006
1	AntibodiesIBA 02/2022

Therapy/Procedure

10	Therapeutics 01/2020 - 06/2003
6	Immunotherapy 01/2014 - 11/2004
1	Activities of Daily Living (ADL) 06/2022
1	Immunomodulation 02/2022